Publication | Closed Access
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary interventionResults from the REPLACE-2 trial
66
Citations
0
References
2004
Year
ThrombosisPercutaneous Coronary InterventionCardiovascular DiseasePercutaneous Coronary InterventionresultsPharmacologyCardiovascular PharmacologyPharmacotherapyReplace-2 TrialEconomic EvaluationMedicineAnticoagulantCardiologyCoronary Artery DiseaseAcute Myocardial Infarction
No additional data available for this publication yet. Check back later!